Athersys Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	1.4yrs
Board average tenure	no data

Recent management updates

Recent updates

CEO

Athersys has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Z. Rosado	Interim Chief Financial Officer	1.4yrs	US$1.51m	no data
Senthil Ranganathan	Vice President of Technical Operations	less than a year	no data	no data
David Russ	Vice President of Supply Chain	less than a year	no data	no data
Manal Morsy	Executive VP & Head of Global Regulatory Affairs	11yrs	no data	no data
Robert Mays	Executive VP	7.5yrs	no data	no data
Rakesh Ramachandran	Head of Information Technology & Communications and VP	7yrs	no data	no data
Sarah Busch	VP of Regenerative Medicine & Head of Business Development	less than a year	no data	no data
Ellen Gurley	Manager of Corporate Communications and Investor Relations	no data	no data	no data

1.4yrs

Average Tenure

Experienced Management: 4LSA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Athersys Management

Management criteria checks 0/4

Key information

Recent management updates

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

CEO, Secretary recently bought €53k worth of stock

Recent updates

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Athersys, Inc. announced delayed annual 10-K filing

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index

Athersys, Inc. Receives A Delisting Determination Letter from Nasdaq

Athersys, Inc. Reports Interim Analysis Results of MASTERS-2 Clinical Study with Multistem in Ischemic Stroke

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

New major risk - Market cap size

Athersys Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Requirement

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Announces Patient Enrollment Begins in Third and Final Cohort of the Phase 2 Matrics-1 Clinical Study Evaluating Athersys' Multistem Following Hemorrhagic Trauma

Athersys Granted Clinical Type B Meeting with FDA for Masters-2 Clinical Trial Protocol Discussion

Athersys, Inc. Provides an Update on Ongoing Clinical Trials with MultiStem for the Treatment of Patients Following Hemorrhagic Trauma (MATRICS-1) and for the Treatment of Ischemic Stroke (MASTERS-2)

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

Athersys Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

CEO, Secretary recently bought €53k worth of stock

Athersys, Inc. to Report Q3, 2022 Results on Nov 15, 2022

Athersys, Inc. Announces the Resignation of Kenneth H. Traub from the Board of Directors

Athersys Receives Non-Compliance Letter from Nasdaq

Athersys, Inc. Announces Favorable Preclinical Results for MultiStem Treatment in Defense Department Radiation Countermeasure Study

Athersys, Inc. Appoints Kasey Rosado as Interim Chief Financial Officer

Athersys, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Athersys, Inc. Designates Dan Camardo as the Principal Financial Officer and Principal Accounting Officer

Athersys, Inc. Announces Board Changes

Athersys, Inc. Announces Management Changes

Athersys, Inc., Annual General Meeting, Jun 15, 2022

Athersys, Inc. to Report Q1, 2022 Results on May 06, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Athersys, Inc. to Report Q4, 2021 Results on Mar 15, 2022

Athersys, Inc. to Present an Outlook of its Ischemic Stroke Program Including Perspectives on the Upcoming TREASURE Study Data Readout

Athersys, Inc. Announces Manuscript Reporting Data from the Company’s Must-ARDS Clinical Trial

Third quarter 2021 earnings released: US$0.071 loss per share (vs US$0.11 loss in 3Q 2020)

New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications

Athersys, Inc. announced that it expects to receive $100 million in funding from Aspire Capital Partners, LLC

Full year 2020 earnings released: US$0.42 loss per share (vs US$0.29 loss in FY 2019)

Athersys, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021

Athersys, Inc. Announces Chief Executive Officer Changes

Athersys, Inc. Announces Chairman Changes

New 90-day high: €1.79

New 90-day high: €1.77

UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma

Athersys, Inc. Announces Board Appointments

New 90-day low: €1.12

Athersys, Inc. Announces Board Changes

Revenue misses expectations

New 90-day low: €1.40

Athersys, Inc. Announces the Resignation of Kenneth H. Traub from the Board of Directors

Athersys, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Athersys, Inc. Announces FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome

New 90-day low - €1.69

New 90-day low - €1.77

First half earnings released

Athersys, Inc. to Report Q2, 2020 Results on Aug 10, 2020

CEO

Leadership Team

Average Tenure